The characterization of ovine genes for atrial, brain, and C-type natriuretic peptides.The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissuesGenetic polymorphism rs6922269 in the MTHFD1L gene is associated with survival and baseline active vitamin B12 levels in post-acute coronary syndromes patients.The New Zealand 1986 very low birth weight cohort as young adults: mapping the road ahead.A cohort study comparing cardiovascular risk factors in rural Maori, urban Maori and non-Maori communities in New Zealand.The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction.B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia.Developing a Tailored Smoking Cessation Intervention for Rheumatoid Arthritis Patients.Exploring perceptions of a rheumatoid arthritis-specific smoking cessation programme.A Kaupapa Māori approach to a community cohort study of heart disease in New Zealand.Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities.Higher prevalence of left ventricular hypertrophy in two Māori cohorts: findings from the Hauora Manawa/Community Heart Study.Efficacy of a Rheumatoid Arthritis-Specific Smoking Cessation Program: A Randomized Controlled Pilot Trial.Genetic markers of repolarization and arrhythmic events after acute coronary syndromes.Metabolic and Blood Pressure Effects of Walnut Supplementation in a Mouse Model of the Metabolic Syndrome.Vitamin C Status Correlates with Markers of Metabolic and Cognitive Health in 50-Year-Olds: Findings of the CHALICE Cohort Study.Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles.Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing.Genetic variation in the renin-angiotensin-aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease.The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design.Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis.New Insights into Cardiac and Vascular Natriuretic Peptides: Findings from Young Adults Born with Very Low Birth Weight.Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cells.Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch.Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome.Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy.Broken heart syndrome -- is it a psychosomatic disorder?Circulating miR-323-3p and miR-652: candidate markers for the presence and progression of acute coronary syndromes.Identifying barriers to smoking cessation in rheumatoid arthritis.Chronic urocortin 2 administration improves cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction.Copy number variants implicate cardiac function and development pathways in earthquake-induced stress cardiomyopathy.Living in areas with different levels of earthquake damage and association with risk of cardiovascular disease: a cohort-linkage studyPlasma levels of soluble VEGF receptor isoforms, circulating pterins and VEGF system SNPs as prognostic biomarkers in patients with acute coronary syndromesIle164 variant of β2-adrenoceptor does not influence outcome in heart failure but may interact with β blocker treatmentNatriuretic peptide system in fetal heart and circulationDendroaspis natriuretic peptide: endogenous or dubious?Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failureAssociation of the aldosterone synthase gene C-344T polymorphism with risk factors and survival in a post-myocardial infarction cohortAngiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort
P50
Q33178165-135BECF3-DE5D-4C4D-B452-A30CB0A9469BQ34328195-40187434-C92D-4B9C-ACCA-68B358A30070Q35117998-3637D56A-37F5-41DD-890C-46B55536B64EQ35737777-2EAC9809-F939-4A72-B3AB-37E595E75540Q36045026-B09ACA06-CBA5-4EE5-8C9D-E1DDC0C62883Q37242460-3324953B-302A-4AE3-AECB-6A09669109B1Q38372146-E35A7CDD-EE5B-4CC0-AB66-49D2907D4901Q38486424-46E82A38-7F75-4C3D-ABC5-9BBCE50E20D0Q38691601-5DBE6EAE-B629-4BDB-9CDA-7E12A373BE8CQ39985246-CB276A62-4C34-44FD-9149-94AA7969D474Q40083247-1C43883C-C770-4973-A001-18A870B53A9DQ40247281-A330AEBA-2BFE-4FAB-9FCA-3C5439354B1EQ40687578-90BA63D8-EDD4-4992-AC00-8D3A0316F457Q41144793-20A9DB24-6FBF-4879-AC48-E17A6427DD0DQ41195251-A8198F08-0A17-4163-9119-C2241D100A34Q41583957-53FD0FDE-3C2D-49E5-99ED-EB5762639F5DQ42501431-2D38F73D-9866-4E5D-BEBF-603E608E71CCQ43552786-9E0B6B16-167E-44FF-8950-3BB1C877D9B0Q45109124-DB1EC434-BB2E-471D-B653-EE3C51018F13Q46344567-9138D906-200D-4517-BD45-4569CABFD984Q46837810-BCD23E20-6D95-4B68-B9DA-785DAC1C35BFQ46865482-62ABE4DD-3E6A-4257-9C81-35DE833170DDQ47178241-39C4110F-F336-4B79-88CF-639F5460829DQ47231130-BE251EBD-3755-4F9A-B102-C8FF4BA119ACQ48833722-EBDBD970-B6D3-4541-8AFB-9AF396F8725AQ48923995-C6163BBD-BF4B-48BC-AD86-FF6FEF204901Q50320378-340DE953-3B27-4117-BC33-ADC2588114DBQ50630265-70E83963-68A8-4078-B8AF-26B96EFCB041Q50847785-814484FC-92BC-407B-A01B-E81F846A5FD3Q51774758-B0CA3C85-193F-4463-8592-6C5F6D16926DQ53624507-88B45B43-8963-4726-A9A5-7D2D0ECF0F43Q55259259-12FDDDB4-281E-4A99-89B7-E3CFE8DC33BBQ57095350-8A84481B-90DE-4B09-AC2C-BE6CD292072CQ58778121-3D590D75-F565-4C6B-AD33-E283750719BEQ60630411-0C118DA4-AD92-4DE2-9BF8-AAE9CAC2A03FQ74100494-890A11EE-46DB-46B4-AC42-8501BC3BD2EEQ77541418-20C19A9D-BEC3-4959-84DA-DC51F8004D2CQ79405149-508021C2-ABAD-4E9A-9218-767C363965C5Q79536266-31E17E07-EAB3-46B3-8393-3D7D2D5342AFQ79621199-380EE36B-0E2C-4701-9D79-6FEC0F55D3E8
P50
description
New Zealand medical researcher
@en
academicus
@nl
հետազոտող
@hy
name
Vicky A. Cameron
@en
Vicky A. Cameron
@es
Vicky A. Cameron
@nl
Vicky A. Cameron
@sq
Vicky Cameron
@fr
type
label
Vicky A. Cameron
@en
Vicky A. Cameron
@es
Vicky A. Cameron
@nl
Vicky A. Cameron
@sq
Vicky Cameron
@fr
prefLabel
Vicky A. Cameron
@en
Vicky A. Cameron
@es
Vicky A. Cameron
@nl
Vicky A. Cameron
@sq
Vicky Cameron
@fr
P106
P21
P31
P496
0000-0003-3147-683X
P569
2000-01-01T00:00:00Z